Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Vistagen Therapeutics (VTGN) EPS (Weighted Average and Diluted) (2023 - 2025)

Vistagen Therapeutics (VTGN) has disclosed EPS (Weighted Average and Diluted) for 9 consecutive years, with -$0.45 as the latest value for Q4 2025.

  • Quarterly EPS (Weighted Average and Diluted) rose 2.17% to -$0.45 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$1.9 through Dec 2025, down 28.38% year-over-year, with the annual reading at -$1.67 for FY2025, 9.87% down from the prior year.
  • EPS (Weighted Average and Diluted) hit -$0.45 in Q4 2025 for Vistagen Therapeutics, up from -$0.54 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of -$0.22 in Q4 2023 to a low of -$1.76 in Q1 2023.
  • Historically, EPS (Weighted Average and Diluted) has averaged -$0.58 across 3 years, with a median of -$0.46 in 2024.
  • Biggest YoY gain for EPS (Weighted Average and Diluted) was 85.77% in 2024; the steepest drop was 109.09% in 2024.
  • Year by year, EPS (Weighted Average and Diluted) stood at -$0.22 in 2023, then crashed by 109.09% to -$0.46 in 2024, then increased by 2.17% to -$0.45 in 2025.
  • Business Quant data shows EPS (Weighted Average and Diluted) for VTGN at -$0.45 in Q4 2025, -$0.54 in Q3 2025, and -$0.47 in Q2 2025.